Tech Transfer Roundup: Coronavirus Research Collaborations Respond To Pandemic
Executive Summary
Recent collaborations involving Ridgeback, Themis, Junshi, Moleculin, Can-Fite, Pluristem and Beroni highlight the intense increase in research in how to treat or prevent COVID-19.
You may also be interested in...
Merck’s Oral Antiviral Data In COVID-19 May Change Pandemic Outlook
Merck/Ridgeback’s ribonucleoside analog shows nearly 50% reduction of risk for hospitalization or death in Phase III study. Firms will seek EUA in US; a contract is in place for 1.7 million courses of therapy.
Coronavirus Update: Trump Spreads Confusion On Drug Treatments, Biogen Fires China Flight Employee
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
CEPI Expands COVID-19 Vaccine Portfolio, But Pleads For Big Funding Boost
As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.